UBS Group’s Biostar Pharmaceuticals, Inc. BSPM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q3 | – | Sell |
-297
| Closed | -$1K | – | 8616 |
|
|
2018
Q2 | $1K | Sell |
297
-689
| -70% | -$1.72K | ﹤0.01% | 7916 |
|
|
2018
Q1 | $3K | Buy |
986
+672
| +214% | +$2.13K | ﹤0.01% | 7499 |
|
|
2017
Q4 | $1K | Sell |
314
-3,320
| -91% | -$5.9K | ﹤0.01% | 7796 |
|
|
2017
Q3 | $5K | Buy |
3,634
+2,446
| +206% | +$3.4K | ﹤0.01% | 7276 |
|
|
2017
Q2 | $2K | Buy |
1,188
+188
| +19% | +$327 | ﹤0.01% | 7458 |
|
|
2017
Q1 | $2K | Sell |
1,000
-1,424
| -59% | -$3.74K | ﹤0.01% | 7367 |
|
|
2016
Q4 | $7K | Sell |
2,424
-4,072
| -63% | -$13.9K | ﹤0.01% | 7135 |
|
|
2016
Q3 | $24K | Buy |
6,496
+1,703
| +36% | +$6.21K | ﹤0.01% | 6180 |
|
|
2016
Q2 | $21K | Buy |
4,793
+3,839
| +402% | +$8.55K | ﹤0.01% | 6291 |
|
|
2016
Q1 | $2K | Buy |
954
+937
| +5,512% | +$2.13K | ﹤0.01% | 7377 |
|
|
2015
Q4 | $0 | Sell |
17
-88
| -84% | -$380 | ﹤0.01% | 8836 |
|
|
2015
Q3 | $1K | Sell |
105
-716
| -87% | -$3.9K | ﹤0.01% | 8318 |
|
|
2015
Q2 | $6K | Buy |
821
+49
| +6% | +$439 | ﹤0.01% | 7833 |
|
|
2015
Q1 | $7K | Sell |
772
-134
| -15% | -$1.08K | ﹤0.01% | 7965 |
|
|
2014
Q4 | $7K | Buy |
+906
| New | +$8.62K | ﹤0.01% | 8763 |
|
UBS Group's BSPM Position: Q3 2018 in Review
UBS Group sold out of Biostar Pharmaceuticals, Inc. (BSPM) in Q3 2018, closing a stake of 297 shares — an estimated $1K sold.
UBS Group first reported a position in BSPM in Q4 2014 and held it in 15 quarters. The position peaked at $24K in Q3 2016. 0 funds tracked by Wall St. Rank hold BSPM as of Q3 2018.
- UBS Group reported no remaining Biostar Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
- UBS Group sold 297 Biostar Pharmaceuticals, Inc. shares in Q3 2018, an estimated $1K.
- UBS Group first reported a position in Biostar Pharmaceuticals, Inc. in Q4 2014 and held it in 15 quarters.
- UBS Group's Biostar Pharmaceuticals, Inc. position peaked at $24K in Q3 2016.
- 0 funds tracked by Wall St. Rank held Biostar Pharmaceuticals, Inc. as of Q3 2018.
Based on UBS Group's 13F filing for Q3 2018, filed 14 Nov 2018.